A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer.

Prostate cancer ranks as the second most common malignancy in males. Prostate cancer progressing on androgen deprivation therapy (ADT) is castration-resistant prostate cancer (CRPC). Poly-ADP ribose polymerase (PARP) inhibitors (PARPis) have been at the forefront of the treatment of CRPC. We aim to...

Full description

Bibliographic Details

Published in:	Current Oncology Vol. 30; no. 10; pp. 9262 - 9276
Main Authors:	Alameddine, Zakaria, Niazi, Muhammad Rafay Khan, Rajavel, Anisha, Behgal, Jai, Keesari, Praneeth Reddy, Araji, Ghada, Mustafa, Ahmad, Wei, Chapman, Jahangir, Abdullah, Terjanian, Terenig O
Format:	Journal Article
Published:	MDPI Oct2023
Online Access:	View this record in EBSCOhost